140 related articles for article (PubMed ID: 22438255)
1. Cotargeting signaling pathways driving survival and cell cycle circumvents resistance to Kit inhibitors in leukemia.
Buet D; Gallais I; Lauret E; Denis N; Lombard B; Guillonneau F; Kosmider O; Loew D; Dusanter-Fourt I; Guillouf C; Mayeux P; Moreau-Gachelin F
Blood; 2012 May; 119(18):4228-41. PubMed ID: 22438255
[TBL] [Abstract][Full Text] [Related]
2. Temporal quantitation of mutant Kit tyrosine kinase signaling attenuated by a novel thiophene kinase inhibitor OSI-930.
Petti F; Thelemann A; Kahler J; McCormack S; Castaldo L; Hunt T; Nuwaysir L; Zeiske L; Haack H; Sullivan L; Garton A; Haley JD
Mol Cancer Ther; 2005 Aug; 4(8):1186-97. PubMed ID: 16093434
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic kit triggers Shp2/Erk1/2 pathway to down-regulate the pro-apoptotic protein Bim and to promote apoptosis resistance in leukemic cells.
Selimoglu-Buet D; Gallais I; Denis N; Guillouf C; Moreau-Gachelin F
PLoS One; 2012; 7(11):e49052. PubMed ID: 23145067
[TBL] [Abstract][Full Text] [Related]
4. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation.
Pan J; Quintás-Cardama A; Kantarjian HM; Akin C; Manshouri T; Lamb P; Cortes JE; Tefferi A; Giles FJ; Verstovsek S
Blood; 2007 Jan; 109(1):315-22. PubMed ID: 16912224
[TBL] [Abstract][Full Text] [Related]
5. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
[TBL] [Abstract][Full Text] [Related]
6. M-COPA suppresses endolysosomal Kit-Akt oncogenic signalling through inhibiting the secretory pathway in neoplastic mast cells.
Hara Y; Obata Y; Horikawa K; Tasaki Y; Suzuki K; Murata T; Shiina I; Abe R
PLoS One; 2017; 12(4):e0175514. PubMed ID: 28403213
[TBL] [Abstract][Full Text] [Related]
7. Prolonged MEK inhibition leads to acquired resistance and increased invasiveness in KRAS mutant gastric cancer.
Choi KM; Cho E; Kim E; Shin JH; Kang M; Kim B; Han EH; Chung YH; Kim JY
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):311-318. PubMed ID: 30466782
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
Gohr K; Hamacher A; Engelke LH; Kassack MU
BMC Cancer; 2017 Nov; 17(1):711. PubMed ID: 29100507
[TBL] [Abstract][Full Text] [Related]
9. ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition.
Ruicci KM; Pinto N; Khan MI; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Nichols AC
Oral Oncol; 2018 Sep; 84():95-103. PubMed ID: 30115483
[TBL] [Abstract][Full Text] [Related]
10. Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors.
Wöhrle FU; Halbach S; Aumann K; Schwemmers S; Braun S; Auberger P; Schramek D; Penninger JM; Laßmann S; Werner M; Waller CF; Pahl HL; Zeiser R; Daly RJ; Brummer T
Leukemia; 2013 Jan; 27(1):118-29. PubMed ID: 22858987
[TBL] [Abstract][Full Text] [Related]
11. Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia.
Minieri V; De Dominici M; Porazzi P; Mariani SA; Spinelli O; Rambaldi A; Peterson LF; Porcu P; Nevalainen MT; Calabretta B
Cancer Res; 2018 Oct; 78(20):5793-5807. PubMed ID: 30154155
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
Salizzato V; Borgo C; Cesaro L; Pinna LA; Donella-Deana A
Oncotarget; 2016 Apr; 7(14):18204-18. PubMed ID: 26919095
[TBL] [Abstract][Full Text] [Related]
13. Binimetinib, a novel MEK1/2 inhibitor, exerts anti-leukemic effects under inactive status of PI3Kinase/Akt pathway.
Sakakibara K; Tsujioka T; Kida JI; Kurozumi N; Nakahara T; Suemori SI; Kitanaka A; Arao Y; Tohyama K
Int J Hematol; 2019 Aug; 110(2):213-227. PubMed ID: 31129802
[TBL] [Abstract][Full Text] [Related]
14. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.
Chapuis N; Tamburini J; Green AS; Vignon C; Bardet V; Neyret A; Pannetier M; Willems L; Park S; Macone A; Maira SM; Ifrah N; Dreyfus F; Herault O; Lacombe C; Mayeux P; Bouscary D
Clin Cancer Res; 2010 Nov; 16(22):5424-35. PubMed ID: 20884625
[TBL] [Abstract][Full Text] [Related]
15. Novel thiazole amine class tyrosine kinase inhibitors induce apoptosis in human mast cells expressing D816V KIT mutation.
Jin Y; Ding K; Wang D; Shen M; Pan J
Cancer Lett; 2014 Oct; 353(1):115-23. PubMed ID: 25088577
[TBL] [Abstract][Full Text] [Related]
16. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
17. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S
Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066
[TBL] [Abstract][Full Text] [Related]
18. SWATH-MS proteomics of PANC-1 and MIA PaCa-2 pancreatic cancer cells allows identification of drug targets alternative to MEK and PI3K inhibition.
Aguilar-Valdés A; Noriega LG; Tovar AR; Ibarra-Sánchez MJ; Sosa-Hernández VA; Maravillas-Montero JL; Martínez-Aguilar J
Biochem Biophys Res Commun; 2021 May; 552():23-29. PubMed ID: 33740661
[TBL] [Abstract][Full Text] [Related]
19. Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells.
Peter B; Bibi S; Eisenwort G; Wingelhofer B; Berger D; Stefanzl G; Blatt K; Herrmann H; Hadzijusufovic E; Hoermann G; Hoffmann T; Schwaab J; Jawhar M; Willmann M; Sperr WR; Zuber J; Sotlar K; Horny HP; Moriggl R; Reiter A; Arock M; Valent P
Leukemia; 2018 Apr; 32(4):1016-1022. PubMed ID: 29249817
[TBL] [Abstract][Full Text] [Related]
20. The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells.
Brünner-Kubath C; Shabbir W; Saferding V; Wagner R; Singer CF; Valent P; Berger W; Marian B; Zielinski CC; Grusch M; Grunt TW
Breast Cancer Res Treat; 2011 Sep; 129(2):387-400. PubMed ID: 21046231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]